R&D Day 2023

from the beginning

R&D Day 2023

Forward-Looking Statements

1. Opening

FY2023 R&D Day presenters

2. R&D Strategy

5DXd ADCs and Next Wave

5DXd ADCs and Next Wave

EXPAND & EXTEND to deliver our technology to more patients

3ADCs launch plan

Progress since R&D Day 2022

Approvalof COVID-19 vaccine and progress

3. Research Capability

Toshinori Agatsuma Career Highlights

Daiichi Sankyo created and launched innovative drugs from its own research laboratories

Long history behind the birth of DXdADC

Swift. Decisive. Courageous.

Establishment of ADC Working Team

Challenges that new ADCs had to overcome

Daiichi Sankyo's DXdADC technology solved conventional challenges

Strategy for ADC research in Daiichi Sankyo as of 2010

Discovery of potent payload

Design of drug-linker capable of demonstrating excellent efficacy

Confirmation of drug potential through animal models

The Future of ADC research and development

Sustainable ADC Development

Science & Technology through Craftspersonship

Crafting New Standards of Care

Data-Driven Drug Discovery (D4)

Improvement of research efficiency and quality of compound design through Cyber DMTA

Identifying Our Next Growth Driver

4. Clinical Progress

EXPAND & EXTEND to deliver our technology to more patients

EXPAND & EXTEND to deliver our technology to more patients

Our Breast Cancer Strategy

TROPION-Breast01

BEGONIA Data Update

DESTINY-Breast01/02/03 pooled analysis for BM

DESTINY-Breast08

Establish and expand DXd ADCs to address the broader spectrum of Breast Cancer

EXPAND & EXTEND to deliver our technology to more patients

Our Lung Cancer Strategy

DESTINY-Lung02 Primary Analysis WCLC 2023

TROPION-Lung01 overall efficacy in NSCLC 2/3L ESMO 2023

TROPION-Lung01 efficacy in non-sq and sq NSCLC ESMO 2023

TROPION-Lung01 Safety ESMO 2023

TROPION-Lung05 ESMO 2023

HERTHENA-Lung01 study WCLC2023

HERTHENA-Lung01study-Efficacy in Brain MetESMO 2023

Ph1/2 Study: SCLC subgroup analysis WCLC 2023

IDeate-1: ES-SCLC Ph2 study

Establish and expand DXd ADCs as new treatment options in Lung Cancer

EXPAND & EXTEND to deliver our technology to more patients

DXd ADCs expanding into new disease areas beyond Breast and Lung

DESTINY-CRC02 Ph2 Primary Analysis ASCO 2023

DESTINY-PanTumor02 ESMO 2023

Ph1/2 Study Data Update ESMO 2023

Ph1 Study OVC Cohort Data Update ESMO 2023

5DXd ADCs are making steady progress toward the vision to deliver their benefits to more patients

Combinations further unlock the potential of DXd ADCs

5DXd ADCs Summary

EXPAND & EXTEND to deliver our technology to more patients

The 6thDXd ADC with broad potential

EXPAND & EXTEND to deliver our technology to more patients

Combinations further unlock the potential of DXd ADCs

Rationale of combination with DXd ADC

Evaluating potential of combination with DXd ADC in clinical trial

Preclinical data support the rationale for the combination of ENHERTU and DS-1103

Evaluating potential of combination with DXd ADC in clinical trial

EXPAND & EXTEND to deliver our technology to more patients

VALENTINE-PTCL01 Primary Results ASH 2023

QuANTUM-First Approvals

QUIWI Ph2 Investigator-Initiated Study Interim Results

A potential first-in-class anti-CD147 Antibody

Next Wave Summary

Clinical Summary

5. Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

• Q&A5

• Q&A6